Rajesh Kumar, HSBC's head of life sciences and healthcare equity research in London, talks Merck, Roche, Novo Nordisk, Lilly, Bayer, and...

Known widely as RNAiAnalyst on twitter, he discusses antisense, RNAi, CRISPR, base editing, ADAR, splicing, and more.

PSCC President Eric Vivier describes the facilities that are being built and other pillars of support that the cluster can offer cancer...

He describes Sofinnova Partners and its numerous investment strategies, the hidden gems of research expertise that can be found...

Emily Fang introduces us to InFocus, a company working on small molecule RNA modulation, and shares her thoughts on the local biotech...

He describes the results of this study, which tested KERENDIA in patients with mildly reduced or preserved ejection fraction.

She describes the study results, offers her opinion on where vutrisiran may enter the treatment paradigm, and shares more about ATTR-CM...

He discusses the sector's IPO activity YTD, what we might expect through the end of the year, and what types of companies have the best...

He describes how technology is changing healthcare at all levels, including hospitals, drug developers, the and patient experience. Plus,...

She describes what motivated her to start the Cancer Vaccine Coalition after a career as a news reporter, promising breast cancer...

Katherine and Hamid describe today's event that is meant for leaders from across healthcare to discuss and think about where the industry...

He recaps this fourth Timmerman Traverse event that raised $1 million for Life Science Cares, and talks about other upcoming climbs....

She describes why she decided to move to the investment side and Sofinnova, what areas of science interest her today, and some thoughts...

Jay Olson shares learnings from a physician survey Oppenheimer conducted on obesity, and comments on Viking, Amgen, Madrigal, Acadia,...

Andrew Tsai shares his take on biotech and discusses Verona, Rapport, Atai Life Sciences, Intra-Cellular, Alto Neuro, Athira, and Relmada.

He talks about the two different categories of companies based on their use of AI, and discusses what he looks for when evaluating them.

NYSE's Eric Dimise and Decoding Bio's Amee Kapadia describe the ways that AI is already impacting healthcare today and where it might be...

Dave Latshaw II predicts how AI might affect organizations of different sizes in biopharma and explains the various ways BioPhy is using...

He provides an in-depth discussion on this week's uniQure data, and upcoming data from Lexeo. Plus, comments on Alnylam, Dyne,...

Noubar Afeyan describes some areas that he sees the funding being deployed, his take on the current state of biotech, the IPO market,...